Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL27627058 | 0.86 | ALDH1A1 (0.53) | ALDH1A1MEN1NPC1KMT2AGAA | |
| Quinoline SCHEMBL28125029 | 0.83 | ALDH1A1 (0.63) | ALDH1A1MEN1NPC1KMT2ARAB9A | |
| Quinoline SCHEMBL27303537 | 0.81 | ALDH1A1 (0.71) | ALDH1A1MEN1NPC1KMT2ARAB9A | |
| Quinoline SCHEMBL1783847 | 0.81 | ALDH1A1 (0.71) | ALDH1A1MEN1NPC1KMT2ARAB9A | |
| Naphthalene SCHEMBL16005359 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MEN1NPC1KMT2AGAA | |
| Quinoline SCHEMBL372690 | 0.80 | ALDH1A1 (0.77) | ALDH1A1MEN1NPC1KMT2ARAB9A | |
| Quinoline SCHEMBL5874493 | 0.80 | ALDH1A1 (0.77) | ALDH1A1MEN1NPC1KMT2ARAB9A | |
| Quinoline SCHEMBL5283313 | 0.80 | ALDH1A1 (0.77) | ALDH1A1MEN1NPC1KMT2ARAB9A | |
| Quinoline SCHEMBL28160669 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MEN1NPC1KMT2ARAB9A | |
| Quinoline SCHEMBL28752073 | 0.79 | ALDH1A1 (0.68) | ALDH1A1MEN1NPC1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345954-B1 | METHODS UTILIZING ARYL THIOIMINES IN SYNTHESIS OF ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2008-06-04 | — | — | EP | claimed |
| EP-1345954-A2 | METHODS UTILIZING ARYL THIOIMINES IN SYNTHESIS OF ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2003-09-24 | — | — | EP | claimed |
| US-6455680-B1 | PROTECTING A KETONE OF A KETONE-CONTAINING ERYTHROMYCIN DERIVATIVE AS AN ARYL THIOIMINE (AR-S-N=) BY REACTING THE KETONE WITH A HYDROXYLAMINE TO FORM AN OXIME, AND THEN REACTING WITH A TRIALKYL PHOSPHINE AND AN ARYL DISULFIDE | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | claimed |
| US-20020115835-A1 | Methods utilizing aryl thioimines in synthesis of erythromycin derivatives | ABBVIE INC. | 2002-08-22 | — | — | US | claimed |
| WO-2002050093-A2 | METHODS UTILIZING ARYL THIOIMINES IN SYNTHESIS OF ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 2002-06-27 | — | — | WO | claimed |
| EP-1345954-B1 | METHODS UTILIZING ARYL THIOIMINES IN SYNTHESIS OF ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1345954-A2 | METHODS UTILIZING ARYL THIOIMINES IN SYNTHESIS OF ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6455680-B1 | PROTECTING A KETONE OF A KETONE-CONTAINING ERYTHROMYCIN DERIVATIVE AS AN ARYL THIOIMINE (AR-S-N=) BY REACTING THE KETONE WITH A HYDROXYLAMINE TO FORM AN OXIME, AND THEN REACTING WITH A TRIALKYL PHOSPHINE AND AN ARYL DISULFIDE | ABBOTT LABORATORIES | 2002-09-24 | — | — | US | disclosed |
| US-20020115835-A1 | Methods utilizing aryl thioimines in synthesis of erythromycin derivatives | ABBVIE INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002050093-A2 | METHODS UTILIZING ARYL THIOIMINES IN SYNTHESIS OF ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115835-A1 | Methods utilizing aryl thioimines in synthesis of erythromycin derivatives | CYP2C9, CYP2B6, POR | ALDH1A1 1376/4885MEN1 4691/4885NPC1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.